SCHEMBL1335652

SCHEMBL1335652

CCc1cccc(N(Cc2ccncc2)C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
PAX8 Q06710 2/20 0.47
JAK2 O60674 1/20 0.47
TSHR P16473 2/20 0.45
GAA P10253 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.44
TSPO P30536 1/20 0.42
GLA P06280 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
CYP2C9 P11712 3/20 0.41
CYP2C19 P33261 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336106 0.81 BCL2A1 (0.50) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL11471585 0.80 SIGMAR1 (0.43) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL1336792 0.77 ALDH1A1 (0.62) RAB9ANPC1ALDH1A1HTTSMN1; SMN2
SCHEMBL1336794 0.77 ALDH1A1 (0.62) RAB9ANPC1ALDH1A1HTTSMN1; SMN2
SCHEMBL1334800 0.77 HDAC1 (0.49) PTGDR2KMT2AMEN1
SCHEMBL1336855 0.77 TSHR (0.49) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL1336782 0.75 GAA (0.60) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL1924742 0.75 RAB9A (0.76) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL20236326 0.75 BCL2 (0.52) RAB9ANPC1ALDH1A1HTTPAX8
SCHEMBL10268291 0.74 KMT2A (0.64) ALDH1A1HTTTSHRGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US claimed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP claimed
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US disclosed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics GPR119, GLP1R, ADIPOR1 RAB9A 4619/4885NPC1 2854/4885ALDH1A1 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.